Blog

Categories
  1. Rezdiffra and Weight Loss Medicines: Rivals or Partners in Treating MASH?

    Can Rezdiffra lead to weight loss and how can it be combined with weight loss medicines as part of your MASH treatment?

    Read more »
  2. What patients should know about ensifentrine, the newest medication for COPD

    All you should know about the newest treatment for COPD, including how it compares to other medicines.

    Read more »
  3. Zolbetuximab for pancreatic cancer: Is approval expected soon?

    What are the latest clinical trial results for zolbetuximab in pancreatic cancer, and is approval expected soon?

    Read more »
  4. Ibudilast for ALS: When is FDA approval coming (and how not to wait)?

    When is Ketas (ibudilast) expected to be approved in the USA, EU, and more? And how can you start your ALS treatment in the meantime?

    Read more »
  5. Can I take Leqembi together with Eliquis?

    Read more »
  6. Kisqali for early breast cancer: Where is it available and how to get it now?

    Where is Kisqali (ribociclib) approved as an adjuvant treatment for early breast cancer (and how to get it if it's not yet in your country)?

    Read more »
  7. Opzelura cream in India: How to get the new vitiligo treatment?

    How to get the new vitiligo ointment from a trusted supplier in India?

    Read more »
  8. Odronextamab's FDA approval: Why it failed and how to get the medicine anyway?

    Odronextamab may not have gotten FDA approval, but it's on its way to getting the EMA's green light. Here's what that means for you as a US patient.

    Read more »
  9. How to navigate Blenrep's withdrawal from the EU and US markets

    Why was Blenrep pulled off the market, is it still available, and will it get approval again?

    Read more »
  10. Enhertu as Tumor-Agnostic Therapy: Important Updates for Non-US Cancer Patients

    When will non-US patients have access to Enhertu as a tumor-agnostic treatment.

    Read more »
  11. Vigafyde: Could the only ready-to-use vigabatrin oral solution be a Sabril alternative?

    How is the new vigabatrin oral solution different from other treatments for infantile spasms? And can it be a Sabril alternative?

    Read more »
  12. Tarlatamab's approval in Europe: When is it coming (and how not to wait)?

    When will the newest treatment for extensive-stage small cell lung cancer be available to patients in Europe (and worldwide)?

    Read more »
  13. Lurbinectedin for Ewing sarcoma and neuroendocrine tumors: Are we there yet?

    Can lurbinectedin be used to treat Ewing sarcoma and neuroendocrine tumors? The latest data and likely approval timelines.

    Read more »
  14. Relyvrio Discontinued: Top Alternatives and How to Continue Your Treatment

    Relyvrio is being pulled off the market. What does it mean for you and your treatment?

    Read more »
  15. Who is a candidate for lecanemab (and how to get the treatment if you qualify)?

    Who qualifies for treatment with lecanemab? And how non-US patients can get the medicine if their doctor prescribes it.

    Read more »
  16. Fruquintinib for gastric cancer: Will it be approved soon?

    Fruquintinib clinical trials in gastric cancer are showing promising results. Will the medicine be approved for this indication soon?

    Read more »
  17. Lurbinectedin's EMA approval: Is it coming (and when)?

    Will Zepzelca be available to European and UK patients soon? Here's what we know, and your options if you can't wait.

    Read more »
  18. Givinostat's role in polycythemia vera treatment: All you need to know

    Can givinostat be used to treat polycythemia vera? Here's what clinical trial data show.

    Read more »
  19. Givinostat's EMA approval: How long do you have to wait (and how not to)?

    When will the new nonsteroidal treatment for Duchenne be available in the EU and the UK?

    Read more »
  20. What types of cancer can Tivdak treat? The latest trial data.

    Could Tivdak treat more than cervical cancer? Here's the latest overview of trials focusing on ovarian, head and neck cancers, and more.

    Read more »
  21. Eflornithine for neuroblastoma: EMA approval timelines and how to avoid waiting

    When will European patients have access to the newest FDA-approved neuroblastoma treatment?

    Read more »
  22. Iptacopan's EMA approval is near. When will the medicine be available to you?

    Iptacopan will soon be approved in Europe, but when will it be available to patients?

    Read more »
  23. Retifanlimab for renal cell carcinoma (and other types of cancer)

    Zynyz(retifanlimab) may have a larger role to play in cancer treatment. Find out the latest research in renal cell carcinoma and more.

    Read more »
  24. Everything about eplontersen's EMA approval (and how to get the treatment sooner)

    When will Wainua be available to patients in Europe and the UK? The latest news and all your options in the meantime.

    Read more »
  25. What types of cancer can toripalimab treat?

    Toripalimab is being studied as a treatment of NSCLC, oesophageal cancer, melanoma, and more. What does research tell us, and what does it mean for you?

    Read more »
  26. Can erdafitinib treat breast cancer? The latest data, in simple terms.

    Can Balversa be used to treat breast cancer? What we know from research, and what it means for you.

    Read more »
  27. When is toripalimab getting its EMA approval (and how not to wait)

    Toripalimab may get its EMA and MHRA approvals soon, but when will it be available to patients? All you need to know.

    Read more »
  28. Tivdak's EMA approval: When is it coming (and what to do if you can't wait)

    When will Tivdak be available to patients in Europe and the UK? All you need to know, and all your options to get the treatment quicker.

    Read more »
  29. Zynyz's EMA approval: When will the treatment be available (and how not to wait)

    Zynyz is close to EMA approval, but it won't be immediately available everywhere in Europe. Here's how to get the treatment at your own timeline.

    Read more »
  30. Erdafitinib's EMA approval: Where are we five years after its first global approval

    Erdafitinib may get its EMA approval in 2024, but when will it be available on the market?

    Waiting for erdafitinib's EMA approvalWaiting for erdafitinib's EMA approval
    Read more »
Page
US United States 0